GlassScriptPhysician profile
Kacey Lohmann
NPI 1962861930
$4,709.99
in general payments reported to CMS, 2019-2025
23 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,841 · 2022: $729 · 2023: $543 · 2024: $245 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $649.75 | 2021-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $467.95 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $390.32 | 2021-2025 | Epclusa |
| Janssen Biotech, INC. | $330.55 | 2021-2025 | Tremfya |
| Madrigal Pharmaceuticals | $297.70 | 2025 | Rezdiffra |
| Ardelyx, INC. | $190.52 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $189.10 | 2025 | Voquezna |
| Genzyme Corporation | $183.28 | 2023-2025 | |
| Pfizer INC. | $109.32 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $80.02 | 2021-2023 | |
| Qol Medical, LLC | $80.00 | 2021-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $79.54 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $77.29 | 2021-2023 | Ocaliva |
| Lilly USA, LLC | $76.24 | 2024 | Omvoh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.15 | 2021-2023 | Dificid |
| Redhill Biopharma INC. | $46.62 | 2021-2022 | |
| Celgene Corporation | $43.47 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $39.54 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $30.21 | 2025 | Zenpep |
| Lucid Diagnostics INC. | $18.41 | 2023 | |
| Evoke Pharma, INC. | $16.56 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Lohmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.